HIGH-PRECISION SARS-COV-2 MOLECULAR DETECTION AND COVID-19 DIAGNOSTICS

Wayne State University, Detroit, Michigan, United States

TECHNOLOGY SUMMARY

Tech Brief: We have developed a novel hyperdimensional nucleic acid detection system with the capability to detect a single absolute copy of SARS-CoV-2 target RNA and a consistent and reliable LoD of 2 copies/µL, the power to factually effectively eliminate false negative outcomes, and an estimated false positive rate of ~0.0%.

---

SHOWCASE SUMMARY

FIGURES OF MERIT

Value Proposition: Molecular diagnostics systems’ manufacturers, as well as health care providers and institutions, dedicated diagnostic and clinical laboratories, and patients and communities in the local, nation-wide, and global domains will directly benefit from the advantage of counting with a novel, high-precision Covid-19 molecular diagnostics platform. Growth potential and business prospective of the present SARS-CoV-2 detection and Covid-19 diagnostics platform includes its use in longitudinal clinical studies, viral load determination assessments, and disease progression and tracking analyses in Covid-19 patients, as well as SARS-CoV-2 detection in sewer and wastewater systems for sentinel programs and surveillance networks for Covid-19 outbreaks, and, also, its large-scale use in systematized testing and probing screenings in dairy products and meat and meat industry foods. The business potential and commercialization prospective of our high-precision SARS-CoV-2 detection and Covid-19 diagnostics platform encompasses a wide and growing market, both in extension and future demand perspectives, across distinct domains of sanitary, production and industry activities. The hyper-specificity and hyper-sensitivity nature of this technology opens a market opportunity for early detection and diagnosis providing a significant differentiation and value-add when compared to current methods. We seek a strategic development and a commercial partner for our first Covid-19 diagnostic platform.